Mexico Active Pharmaceutical Ingredient (API) Market Overview, 2027

"The API manufacturing sector in Mexico has experienced significant growth in recent years, attracting both domestic and foreign investment. Many multinational pharmaceutical companies have set up manufacturing facilities in Mexico to take advantage of the country's competitive advantages and access to the North American market. Additionally, Mexico has also seen the development of local API manufacturers, contributing to the growth of the industry. Mexico has a well-developed and highly skilled labor force in the pharmaceutical and chemical sectors. The country has a strong tradition in chemical manufacturing, which provides a solid foundation for API production. Mexico has experienced a steady expansion of its pharmaceutical industry, driven by factors such as population growth, rising healthcare demands, and an increasing focus on research and development. The expansion of API production is intimately related to the changing healthcare environment thus creating new opportunities for API manufacturers who can produce high-quality APIs that can help to treat disease. Mexico is a cost-effective site for API manufacture since it has lower manufacturing costs than many wealthy nations. A worldwide regulatory framework for the production of pharmaceuticals is followed in Mexico. The governing body in charge of monitoring pharmaceutical products and making sure that Good Manufacturing Practices (GMP) are followed is the Federal Commission for the Protection against Sanitary Risk (COFEPRIS). API manufacturing operations are supported by Mexico's well-developed infrastructure, which includes industrial parks, transportation systems, and utilities. The United States-Mexico-Canada Agreement (USMCA), which improves trade and market access for pharmaceutical goods made in Mexico, is one of a number of free trade accords with which Mexico is affiliated. Manufacturers are increasingly focusing on environmentally friendly practices by implementing green chemistry principles. This involves using sustainable raw materials, minimizing waste generation, and optimizing chemical processes to reduce environmental impact. According to the report titled ""Mexico Active Pharmaceutical Ingredients Market Outlook, 2027"" published by Bonafide Research, the market is expected to grow exorbitantly over the forecast period. Though synthetic APIs are widely used to manufacture drugs, biotech APIs are expected to grow rapidly over the forecast period. The availability of cutting-edge technologies, research facilities, and academic institutions fosters innovation in API manufacturing processes and techniques. The captive API segment accounted for the major market share and is expected to grow at a steady CAGR over the forecast period. The manufacturing market in Mexico has been experiencing steady growth over the years. The demand for APIs is primarily driven by the increasing need for generic drugs, advancements in drug development, and the rising prevalence of chronic diseases. The United States has one of the largest generic drug markets globally. The manufacturing of API drugs in Mexico is distributed across various segments, but the highest manufacturing volume typically occurs in the generic drug segment. Generic APIs are expected to be in demand over the forecast period as the branded API segment's demands are declining. This is due to the consolidation in the pharma industry and various drugs going off-patent. Due to a rise in over-the-counter drugs and the lower cost of generic drugs, it is expected to lure consumers. The increasing number of cardiovascular diseases, diabetes, respiratory diseases, cancers, and other chronic diseases, which are long-lasting and require the patient to consume the drugs on a daily basis, drive the demand for cheaper alternatives to save costs. Thus, the demand for generic API will rise in future years coupled with government incentives. The cardiovascular diseases segment accounts for the largest application due to increasing heart-related diseases worldwide. Rising awareness, preventive treatment, and government measures are further expected to drive future demand for API. On the other hand, oncology applications are expected to grow rapidly over the forecast period due to the changing lifestyles of millennials and the growing number of cancer patients in recent years. The metabolic disorders caused by sedentary lifestyles and hormonal imbalances created in the human body are the factors increasing the risks of these diseases. Diabetes is another chronic disease that is on the rise among the populace in the country. The COVID-19 pandemic brought attention to the value of indigenous medication production capacity and supply chain resilience. The pandemic also caused disruptions to the supply chain for APIs. This was due to a number of factors, including factory closures, travel restrictions, and shortages of raw materials. In 2020 the manufacturing of drugs decreased by -2.80% due to supply chain logistics which were at a standstill. However, the future markets are projected to grow exorbitantly as they have recovered from the pandemic shocks. Many manufacturing units in China were shut down due to a lack of raw materials and the pandemic effects which affected the world markets for API. Also, the decrease in demand for pharmaceuticals for certain elective procedures has also led to a decline in the market's growth in 2020. These disruptions made it difficult for API manufacturers to obtain the materials they needed to produce APIs, which led to shortages of some APIs. Due to this factor, there is now more interest in promoting and funding domestic API production to maintain a steady supply of life-saving medications in the event of catastrophes or breakdowns in the global supply chain.

API manufacturers in Mexico are pursuing to meet the growing demand for pharmaceutical products. The industry continues to evolve and adapt to advancements in science, technology, and patient needs. API manufacturers are increasingly partnering with research institutions, startups, and other industry stakeholders to foster collaboration and open innovation. By sharing knowledge, resources, and expertise, they can accelerate the development of new ideas and bring innovative products to market more rapidly. API manufacturers are also using new technologies, such as artificial intelligence (AI) and machine learning, to improve their manufacturing processes. These technologies are used to optimize process parameters, predict yields, and identify potential problems. Considered in this report ? Geography: United States (US) ? Historic Year: 2016 ? Base year: 2021 ? Estimated year: 2022 ? Forecast year: 2027 Aspects covered in this report United States • Active Pharmaceutical Ingredients Market with its value, forecast, and segments • Application wise Active Pharmaceutical Ingredients distribution • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Ask an Expert

Manmayi Raval

Research Consultant

Based on a synthesis of Active Pharmaceutical Ingredients in the report • Synthetic API • Biotech API Based on the drug type of Active Pharmaceutical Ingredients in the report • Branded API • Generic API Based on the type of manufacture of Active Pharmaceutical Ingredients in the report • Captive API • Merchant API

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

By Therapeutic Application Type in the report • Communicable Diseases • Oncology • Diabetes • Cardiovascular Disease • Pain management • Respiratory Diseases • Other Therapeutic Applications The approach of the report This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual reports of companies, and analyzing government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources. Intended audience This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the pharmaceutical industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry. Please get in touch with our sales team to find out more."